Literature DB >> 15963079

A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses.

L Gatta1, A Zullo, F Perna, C Ricci, V De Francesco, A Tampieri, V Bernabucci, M Cavina, C Hassan, E Ierardi, S Morini, D Vaira.   

Abstract

BACKGROUND: A standard third-line treatment is lacking, and European guidelines recommend performing culture in these patients. However, the use of this procedure as 'routine practice' is definitively not feasible. AIM: To evaluate the eradication rate of a 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses for Helicobacter pylori.
METHODS: A total of 151 patients with persistent Helicobacter pylori infection after two treatments were studied. Patients were considered positive if two of three endoscopic tests were positive. Susceptibility testing was also performed. Patients received a standard dose of proton-pump inhibitors twice daily, levofloxacin 250 mg twice daily and amoxicillin 1 g twice daily, for 10 days. Endoscopic follow-up was carried out 4-6 weeks after the end of eradication therapy.
RESULTS: About 76% (95% CI: 68.8-82.3), and 85% (95% CI: 77.5-89.7) of patients were eradicated according to intention-to-treat and per-protocol analysis, respectively. Eradication rates of the strains showed as 92% (95% CI: 83.2-96.7) of those resistant to both metronidazole and clarithromycin but susceptible to levofloxacin.
CONCLUSIONS: In patients who failed previous regimens, the 10-day levofloxacin-based triple therapy is safe and effective, allowing eradication in almost 80% of the patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963079     DOI: 10.1111/j.1365-2036.2005.02522.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  30 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 2.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 3.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

4.  Cancer prevention and control: alarming challenges in China.

Authors:  Ann M Bode; Zigang Dong; Hongyang Wang
Journal:  Natl Sci Rev       Date:  2015-08-29       Impact factor: 17.275

5.  Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Authors:  Javier P Gisbert; Jesús Barrio; Inés Modolell; Javier Molina-Infante; Angeles Perez Aisa; Manuel Castro-Fernández; Luis Rodrigo; Angel Cosme; Jose Luis Gisbert; Miguel Fernández-Bermejo; Santiago Marcos; Alicia C Marín; Adrián G McNicholl
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

6.  Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

Authors:  Omero Alessandro Paoluzi; Giovanna Del Vecchio Blanco; Emanuela Visconti; Manuela Coppola; Carla Fontana; Marco Favaro; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 7.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

8.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

9.  Furazolidone therapy for Helicobacter pylori: is it effective and safe?

Authors:  Vincenzo De Francesco; Enzo Ierardi; Cesare Hassan; Angelo Zullo
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

Review 10.  The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Authors:  Angelo Zullo; Vincenzo De Francesco; Cesare Hassan; Sergio Morini; Dino Vaira
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.